CytomX Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by CytomX Therapeutics, Inc. on February 7, 2022, regarding events occurring on February 2, 2022. The Company is a biopharmaceutical entity incorporated in Delaware, with its principal executive offices in South San Francisco, CA.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive personnel changes and associated compensation adjustments.
Material Changes
The primary material change reported is the promotion of Dr. Amy Peterson to President and Chief Operating Officer (COO), effective February 2, 2022. Previously, she served as Executive Vice President and Chief Development Officer. Dr. Sean McCarthy remains Chairman and Chief Executive Officer (CEO) but relinquished the title of President to Dr. Peterson, who will continue to report to Dr. McCarthy.
Compensatory Arrangements and Management Commentary
In connection with the promotion, the Board of Directors approved the following compensatory adjustments for Dr. Peterson:
- Base Salary: Increased to $550,000 annually.
- Bonus Target: Discretionary annual bonus target set at 50% of base salary, contingent on performance.
- Stock Options: Granted an option to purchase 200,000 shares of common stock under the 2015 Equity Incentive Plan with an exercise price of $4.13 (the closing price on February 2, 2022).
- Restricted Stock Units (RSUs): Granted 40,000 RSUs.
The filing contains no specific guidance, outlook, risk factors, or contingencies beyond the standard disclosure of the executive appointment.
Key Facts for Investor Verification
- Verify the impact of the leadership transition on the Company's development pipeline and operational strategy.
- Confirm the dilution impact of the 200,000 stock options and 40,000 RSUs granted to Dr. Peterson.
- Review the Company's 2015 Equity Incentive Plan to understand the vesting schedule and terms of the new grants.
- Monitor future filings for any additional changes to the executive compensation structure or board composition.